Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Platinum-drugs Ototoxicity in Pediatric Patients With Brain Tumors: A 10-Year Review
Publication

Publications

Platinum-drugs Ototoxicity in Pediatric Patients With Brain Tumors: A 10-Year Review

Title
Platinum-drugs Ototoxicity in Pediatric Patients With Brain Tumors: A 10-Year Review
Type
Article in International Scientific Journal
Year
2020
Authors
Rabico Costa, D
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Gil da Costa, MJ
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Barbosa, JP
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Bom Sucesso, M
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Jorge Spratley
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
Vol. 42
Pages: E25-E31
ISSN: 1077-4114
Other information
Authenticus ID: P-00R-GGY
Resumo (PT):
Abstract (EN): Purpose: Platinum-derived chemotherapy is one of the cornerstones in the treatment of central nervous system tumors in children. We aimed to assess the incidence of hearing loss in children after the exposure to platinum drugs. Material and Methods: Retrospective study of prospectively collected data on children consecutively diagnosed with brain tumors and treated with platinum derivatives at a tertiary referral hospital between January 2006 and December 2015. We analyzed multiples variables, such as: age at diagnosis, tumor location, hydrocephalus, platinum drug type, radiotherapy, and follow-up time. The final sample size was 51 patients. Results: The median age at diagnosis was 6 years. The median overall follow-up time was 75 months. The incidence of ototoxicity was 23.5%. Rates of hearing loss with carboplatinum were lower than with cisplatinum. A statistically significant association occurred between the presence of hydrocephalus, radiotherapy exposure, infratentorial tumor location, and ototoxicity after treatment with platinum derivatives. Conclusions: Childhood central nervous system tumors nowadays exhibit improved cure and survival rates. However, the ototoxicity resulting from the chemotherapy treatment may accompany patients for the rest of their lives. This study reveals that this occurrence is not negligible, and the association of radiotherapy and the presence of hydrocephalus can be potentiating factors.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 7
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

The MTHFR C677T and A1298C polymorphisms and susceptibility to childhood acute lymphoblastic leukemia in Portugal (2005)
Article in International Scientific Journal
Oliveira, E; Alves, S; Quental, S; Ferreira, F; Norton, L; Costa, T; Amorim, A; Prata, MJ
Neutrophil dysfunction in a case of glucose-6-phosphate dehydrogenase deficiency (2002)
Article in International Scientific Journal
Costa, E; Vasconcelos, J; Santos, E; Laranjeira, A; Melo, JC; Barbot, J
Neonatal Alloimmune Neutropenia: Still a Diagnostic and Therapeutical Challenge (2012)
Article in International Scientific Journal
Agueda, S; Rocha, G; Ferreira, F; Vitor, B; Lima, M; Guimarães H
Embryonal Tumors of the Central Nervous System: The WHO 2016 Classification and New Insights (2021)
Article in International Scientific Journal
Pinheiro, JAF; de Almeida, JCM; Lopes, JM
Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-15 at 18:17:46 | Privacy Policy | Personal Data Protection Policy | Whistleblowing